Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Simoes C, Villar S, Ariceta B, Garcés JJ, Burgos L, Alignani D, Sarvide S, Martínez-Cuadrón D, Bergua JM, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez-Lorenzo JL, Vidriales MB, Chillon C, Labrador J, Falantes JF, Sayas MJ, Ayala R, Martinez-Lopez J, Pierola AA, Calasanz MJ, Prosper F, San-Miguel JF, Sanz MÁ, Paiva B, Montesinos P; PETHEMA cooperative study group. Simoes C, et al. Among authors: pierola aa. Br J Haematol. 2023 Jun;201(6):1239-1244. doi: 10.1111/bjh.18815. Epub 2023 Apr 14. Br J Haematol. 2023. PMID: 37057357 No abstract available.
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.
Simoes C, Chillon MC, Martínez-Cuadrón D, Calasanz MJ, Vridiales MB, Vazquez I, Hernández-Ruano M, Ariceta B, Aguirre-Ruiz P, Burgos L, Alignani D, Sarvide S, Villar S, Pierola AA, Prosper F, Ayala R, Martínez-López J, Bergua Burgues JM, Vives S, Perez-Simon JA, Garcia-Fortes M, Bernal Del Castillo T, Colorado M, Olave M, Rodríguez-Gutiérrez JI, Labrador J, González M, San-Miguel JF, Sanz MÁ, Montesinos P, Paiva B. Simoes C, et al. Among authors: pierola aa. Blood Adv. 2023 Jan 10;7(1):167-173. doi: 10.1182/bloodadvances.2022008141. Blood Adv. 2023. PMID: 36240453 Free PMC article.
First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
Narayan R, Piérola AA, Donnellan WB, Yordi AM, Abdul-Hay M, Platzbecker U, Subklewe M, Kadia TM, Alonso-Domínguez JM, McCloskey J, Bradford K, Curtis M, Daskalakis N, Guttke C, Safer K, Hiebert B, Murphy J, Li X, Duchin K, Esteban D. Narayan R, et al. Among authors: pierola aa. Clin Transl Sci. 2024 Mar;17(3):e13742. doi: 10.1111/cts.13742. Clin Transl Sci. 2024. PMID: 38494922 Free PMC article. Clinical Trial.
CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil.
Hungria V, Piérola AA, Filho JS, Crusoe E, Filho RJPM, Maiolino A, Rodríguez-Otero P. Hungria V, et al. Among authors: pierola aa. Hematol Transfus Cell Ther. 2023 Apr-Jun;45(2):266-274. doi: 10.1016/j.htct.2022.08.002. Epub 2022 Sep 20. Hematol Transfus Cell Ther. 2023. PMID: 36243623 Free PMC article.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases.
Patnaik MM, Pierola AA, Vallapureddy R, Yalniz FF, Kadia TM, Jabbour EJ, Lasho T, Hanson CA, Ketterling RP, Kantarjian HM, Tefferi A, Garcia-Manero G. Patnaik MM, et al. Among authors: pierola aa. Leukemia. 2018 Nov;32(11):2512-2518. doi: 10.1038/s41375-018-0143-8. Epub 2018 Apr 25. Leukemia. 2018. PMID: 29749401 Free PMC article. No abstract available.
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Montalban-Bravo G, et al. Among authors: pierola aa. Oncotarget. 2018 Jan 3;9(11):9714-9727. doi: 10.18632/oncotarget.23882. eCollection 2018 Feb 9. Oncotarget. 2018. PMID: 29515765 Free PMC article.